DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SAN DIEGO, Dec. 12, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for investors who purchased NASDAQ:PTCT shares against PTC Therapeutics, Inc. over alleged Securities Laws Violations.
Investors, who purchased shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) prior to May 2014 and currently hold any of their NASDAQ:PTCT shares, have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
On March 3, 2016, a lawsuit was filed against PTC Therapeutics, Inc. over alleged securities laws violations. The plaintiff claims that the defendants made allegedly false and/or misleading statements and/or failed to disclose that the Company’s NDA for Translarna that it submitted to the FDA was not sufficiently complete to permit a substantive review of the application, that, as such, the application would not be reviewed nor approved by the FDA, that the impending non-approval of the NDA would have a negative material impact on the Company’s operations and prospects, and that, as a result of the foregoing Defendants’ statements about PTC Therapeutics’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On January 13, 2017, an amended consolidated complaint was filed and the defendants filed their motion to dismiss the case on February 14, 2017. On August 28, 2017, the court denied in part the defendants motion to dismiss the case.
Those who purchased PTC Therapeutics, Inc. (NASDAQ:PTCT) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
